Funding History

Rilemo’s development has been supported by a balanced mix of non-dilutive grants, founders’ capital, and early-stage angel investment, enabling the company to advance R&D, validation, and market readiness while preserving capital efficiency.

Rilemo has secured approximately €500k in non-dilutive grants from institutional partners including Politecnico di Milano, INFN, and Università degli Studi di Milano, as well as national and European innovation programs. These resources supported key technical milestones, prototype development, and early validation without equity dilution.

The founding team contributed around €100k of personal capital prior to the company’s incorporation, demonstrating strong commitment and alignment with the long-term vision. This early investment was instrumental in sustaining operations and advancing strategic activities during the project’s pre-foundation and initial development stages.

A €512k SAFE round was subscribed by a network of business angels to strengthen Rilemo’s capabilities beyond capital provision. The round was designed to complete the team’s skill map and bring on board individuals able to contribute with their expertise, industry insight, and professional networks to support the company’s growth. Details on the structure, terms, and expected cap table impact are provided in

Cap Table.

This funding mix enabled Rilemo to progress from concept to pre-clinical validation and supports the company’s next phase toward certification and commercialization.